Stifel raises Zimmer Biomet stock price target on strong quarter

Zimmer Biomet reported Q3 2026 revenue of $2.06 billion, beating consensus by $23 million, and adjusted EPS of $1.90 versus $1.88 expected; the company also raised its full-year outlook. Stifel lifted its price target to $125 from $110 and maintained a Buy rating, while Monogram’s expected launch moved forward to H1 2027 from 2028, pending FDA clearance. Strength in hips and several technology-related segments was partly offset by knee sales missing estimates amid sales-force transition and China market conditions.

Analysis

The key question is whether growth is converting into earnings, not whether the quarter beat: adjusted EPS was flat year over year despite revenue growth. That makes mix, execution costs and the sales-force transition important checks before extrapolating the top-line momentum. Hip strength and faster growth in technology/data may help defend share against competitors such as Stryker and Smith+Nephew, but a faster Monogram timetable is not yet an earnings catalyst: FDA clearance, launch execution and surgeon adoption remain unproven. Robotics growth may also be coming from a smaller base; verify its revenue contribution and whether adoption expands procedure volume or mainly shifts existing demand.

Near term, raised guidance and estimate revisions support sentiment, but the stock’s proximity to its 52-week high raises the bar for another positive surprise. Over 1–3 months, watch Phase 3 sales-force execution, knee sales recovery and China conditions. Over 6–18 months, Monogram clearance and commercial uptake could change the competitive narrative; delay or weak adoption would remove a source of optionality. The contrarian check: optimistic commentary on demand can obscure the flat EPS comparison and transition friction. A worsening knee trend or guidance that fails to translate revenue growth into EPS would challenge the bullish case.

Key Decisions for Investors

• Do not chase the post-results strength solely on analyst target increases. For new exposure, stage entries after a pullback or wait for evidence that sales-force Phase 3 execution is improving knee performance; no valuation data here supports a price target.
• For existing ZBH exposure, retain a constructive but measured stance while tracking quarterly EPS conversion alongside revenue, knee growth, and any quantified transition costs. Reassess if guidance is cut or earnings fail to progress with sales.
• Treat Monogram as a 6–18-month watch item, not near-term modeled earnings: verify FDA timing, launch readiness, and adoption evidence before assigning meaningful value to the accelerated timetable.
• Monitor China-related knee demand and competitive share signals, including commentary from Stryker and Smith+Nephew. A sustained ZBH knee shortfall or a further deterioration in EPS conversion would falsify the improving-execution thesis.